The White House officially launched its direct-to-patient prescription drug portal, TrumpRx, yesterday evening, aiming to expand access to discounted brand-name medications.

President Donald Trump and CMS Administrator Mehmet Oz positioned the portal as an avenue to reduce out-of-pocket costs – particularly for cash-paying patients. The site connects consumers directly to participating manufacturers’ online purchasing channels, with discounts negotiated under the broader Most Favored Nation pricing agreements.

In practice, TrumpRx may ultimately have more symbolic value than meaningful real-world impact. The program serves cash-pay patients only, and purchases generally do not count toward insurance deductibles or out-of-pocket maximums. As a result, patients with high-deductible plans could pay more by bypassing their insurance requirements.

For manufacturers and payers, TrumpRx raises strategic questions around how discounts are structured, how patient access programs are positioned, and how direct-to-consumer communications are managed.

The platform has already drawn scrutiny from congressional and regulatory stakeholders and academics alike. Democratic lawmakers and consumer advocates have raised concerns that TrumpRx could skirt the federal Anti-Kickback Statute. Others have flagged potential conflicts of interest in the site’s administration through a company affiliated with Trump’s son.

– Stephen Tellone, Associate Director

More than two years after approval, Casgevy has reached only a small number of patients with sickle cell disease globally. Its manufacturer, Vertex Pharmaceuticals, says the slow update isn’t because of waning demand, but because of an unexpected bottleneck at the first step: collecting enough viable cells to manufacture the therapy.

As STAT details, repeated hospitalizations, unpredictable timelines, manufacturing inefficiencies and physically taxing collection processes have slowed treatment and, in some cases, forced patients to abandon the journey altogether – a devastating reality for people living with a disease associated with an average life expectancy of roughly 50 years.

The result is a stark reminder that regulatory approval and a confident commercial narrative are only the beginning. In practice, operational realities – from manufacturing constraints to care delivery logistics – can be just as determinative of access as clinical promise or payer coverage.

For health care communicators, this moment is a reminder that access cannot be reduced to coverage, reimbursement or patient assistance alone. That framing may work for pills, pens or even many procedures, but it breaks down for complex therapies where the closer analog is a system-dependent intervention. In these cases, access is shaped by manufacturing timelines, individualized production, treatment-center readiness, care coordination, patient support and time.

The message is simple but urgent: Commercialization communications must reflect the full operational reality – not just the sticker price or a shock headline.

– Leah Nebbia, Senior Group Director

The Federal Trade Commission secured a landmark settlement this week with Express Scripts, resolving allegations that the PBM artificially inflated insulin prices through anticompetitive rebating practices. The 10-year agreement extends well beyond insulin, mandating structural changes to Express Scripts’ core operating model.

Under the deal, Express Scripts must stop favoring high-priced drugs over identical lower-cost alternatives on standard formularies. The company will implement a standard plan offering in which patient out-of-pocket costs are tied to net drug prices rather than list prices – a move that the FTC estimates could save patients up to $7 billion over the next decade.

Additional requirements include annual drug-level cost reporting to employers; disclosure of payments to insurance brokers; and the creation of a standard offering that allows the plan sponsor to transition away from rebate guarantees and spread pricing. Express Scripts must also transition its pharmacy reimbursement model to one based on actual acquisition costs plus dispensing fees, which could generate millions in new revenue for community pharmacies.

Express Scripts also agreed to integrate TrumpRx into its standard offerings. Purchases through the direct-to-consumer drug platform will count toward patient deductibles and copays, positioning the program within mainstream pharmacy benefits. The settlement also demands Express Scripts reshore its Swiss-based purchasing organization Ascent, bringing over $750 billion in drug purchasing activity back to U.S. soil.

An independent monitor will oversee compliance for three years, although Adam Fein wonders whether the “meeting competition” clause will create a loophole that allows minimal actual changes due to plan sponsor demands. While the FTC case against CVS Caremark and Optum continues, the Express Scripts’ agreement marks a turning point in PBM regulation and provides a roadmap to shape future statutory requirements for the industry.

– Leslie Isenegger, Head, Client Development, RC Resolve

• Feb. 9 – remarks from HHS Secretary Kennedy on “one year of Making America Healthy Again,” The Heritage Foundation
• Feb. 11 – subcommittee hearing on “lowering health care costs” in “the prescription drug supply chain,” House Energy and Commerce
• Feb. 11-13 – annual convening of “the Davos of the access world,” 2026 US ACCESS Forum

• “Companies are right to protect their ability to fund future innovation. But guarding pricing methodology creates the perception that costs can’t be defended, which invites the scrutiny pharma wants to avoid as it raises prices.” – Joshua R. Mansbach, BioSpace
• “The world’s largest pharmaceutical companies are investing some $500 billion to reshore production of critical medications. My most favored nation agreements to lower drug prices by up to 90% could not have happened without the threat of tariffs.” – President Donald Trump, The Wall Street Journal
• “Physicians do not go to medical school to let insurers tell them how to practice medicine.” – Kathy Oubre, RealClearHealth

• Congress passed bipartisan PBM reforms aimed at boosting transparency and restraining middlemen practices, but broader structural changes aren’t expected soon. Pink Sheet: PBM Reform Bill Passes US Congress, But More Changes Likely Not Imminent.
• In a court filing, HHS indicated it would scrap plans for a 340B rebate model pilot and potentially restart the administrative process later. Bloomberg Law: Hospitals, HHS Drop Legal Battle Over Drug Rebate Pilot Program.
• The UK’s science minister projects a spending increase of £1 billion through 2029 under the nation’s new drug pricing agreement with the United States. Endpoints: UK’s health department expected to spend £1B in pharma trade deal with US.
• Despite federal threats to crack down on flashy prescription drug ads in the U.S., several pharma and telehealth companies will air business-as-usual Super Bowl ads on Sunday. STAT: The FDA wants to rein in drug ads. On Super Bowl Sunday, it will be business as usual.
• After firing the government’s vaccine experts, HHS Secretary Kennedy has tasked a panel of new advisers with prioritizing vaccine harms over efficacy, a pivot that could undermine public confidence. Politico: ‘Efficacy will be secondary’: RFK Jr.’s vaccine advisers have a new mission.
• Trump administration officials vetoed an FDA proposal to fast-track Compass’ psilocybin therapy for severe depression, highlighting internal political tension over psychedelic treatments. STAT: Trump administration officials blocked FDA effort to fast-track review of psychedelic treatment.
• One month into the implementation of Medicare’s first 10 negotiated drug prices, early analysis suggests it is still unclear whether seniors are seeing real savings. Endpoints: First 10 Medicare-negotiated drug prices have taken effect: Are seniors really saving money?
• Florida’s FDA-authorized effort to import cheaper Canadian drugs has stalled due to resistance from Canadian suppliers, despite the state’s $82 million investment. Politico: DeSantis’ Canadian drug import plan in Florida goes from campaign trail to tough realities.
• Sellers on social media are running “giveaway” contests that offer unlicensed weight-loss drugs as prizes, drawing warnings from safety experts. The Guardian: Unlicensed weight-loss drugs marketed on social media as ‘prizes.’